Eikon Therapeutics, INC Form 4 insider transactions

Eikon Therapeutics' Chief Operating Officer, Michael A Klobuchar, was granted 87,157 stock options with a $14.88 exercise price.

Eikon Therapeutics Director Robert Luther Huffines was granted 25,873 stock options with an exercise price of $14.88, vesting monthly over four years.

Eikon Therapeutics Director Kenneth C. Frazier has acquired 25,873 stock options with an exercise price of $14.88, vesting monthly over four years.

Eikon Therapeutics' CEO, Roger M. Perlmutter, was granted 268,176 stock options with an exercise price of $14.88, vesting over four years.

Eikon Therapeutics, Inc. granted 67,044 stock options to Benjamin Bruno Thorner, General Counsel and Chief Business Officer, with an exercise price of $14.88.

Eikon Therapeutics' Chief Medical Officer, Roy D. Baynes, was granted 134,088 stock options with an exercise price of $14.88, vesting over 48 months.

Eikon Therapeutics' Chief Financial Officer, Alfred Lloyd Bowie Jr., was granted 67,044 stock options with an exercise price of $14.88.

Eikon Therapeutics CEO Roger M Perlmutter converted preferred stock holdings into common stock ahead of the company's initial public offering.

The Column Group entities converted preferred stock to common shares and purchased additional Eikon Therapeutics common stock at $18 per share, as disclosed in a future-dated SEC Form 4.